In 1991, Guangzhou Baiyunshan Qiaoguang Pharmaceutical Factory joined forces with Japanese partners to plant its first seed in the fertile soil of Lingnan. In the years that followed, as a wholly-owned subsidiary of Mitsubishi Tanabe Pharma (ranked among the world’s top 50 pharmaceutical companies) in China, Green Cross was steeped in the Japanese pharmaceutical ethos of “gentleness, stability, and long-termism,” embedding the principle that “quality is life” into every detail of its manufacturing processes. In 2014, Chairman Liang Feng led his team in completing a full acquisition, ushering in a new era characterized by “Japanese excellence on the outside and Chinese dynamism on the inside”—preserving tradition while embracing innovation.

Over the past three decades, Green Cross has cultivated a dual DNA of “innovation and generic drug development,” holding 59 drug approvals:

Amino Acids: The company established its industry-leading position by launching several domestically pioneering amino acid formulations;

Bioequivalence Evaluation: Proactively embracing national centralized procurement, seven products have successfully won bids, covering 32 provinces and municipalities nationwide, thereby generating strong cash flow to fuel the next wave of innovation.

We firmly believe: We hone our sword through generic drugs and forge ahead toward innovation; every step we take in following the trend paves the way for our future leadership. We forge our spirit through innovation and dedicate ourselves to health, transforming every spark of inspiration into well-being for millions of households.

2 major R&D centers

4 major marketing centers

5 major manufacturing bases

We have established a fully integrated, end-to-end process spanning from molecular discovery to patient access, ensuring that every tablet reaches the clinical front lines with maximum efficiency and at optimal cost.

A pipeline of 11 candidates, focusing on major diseases such as metabolic and autoimmune disorders;

GCF20211, GCF20212, and GCF20215 have entered the IND application drafting phase, with five animal studies proceeding in parallel;

With over 150 R&D professionals led by senior scientists from China and abroad, we are collaborating closely with top institutions such as Zhejiang University, Shenyang Pharmaceutical University, the University of California, and University College London to build an open and collaborative innovation ecosystem.

Our core management team has an average of over 20 years of industry experience, combining the rigor of foreign-funded companies with the strategic vision of state-owned enterprises and the agility of local firms;

Culturally, we uphold the Japanese values of “moderation and stability” while integrating local traits of “ambition, efficiency, pragmatism, and inclusivity,” enabling talent from diverse backgrounds to thrive together at Green Cross.

Guided by our core values of “Protecting Life, Pursuing Excellence, and Integrity and Pragmatism,” we focus on major diseases that threaten human health and are committed to becoming a trusted guardian of a healthy China and a leading domestic research-based pharmaceutical company.